Cargando…

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Mutations in the nucleophosmin 1 (NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of NPM1 mutated (NPM1(mut)) AML, we assess mutation status of five recurrently mutated oncogenes in 129 paired NPM1(mut) samples...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cocciardi, Sibylle, Dolnik, Anna, Kapp-Schwoerer, Silke, Rücker, Frank G., Lux, Susanne, Blätte, Tamara J., Skambraks, Sabrina, Krönke, Jan, Heidel, Florian H., Schnöder, Tina M., Corbacioglu, Andrea, Gaidzik, Verena I., Paschka, Peter, Teleanu, Veronica, Göhring, Gudrun, Thol, Felicitas, Heuser, Michael, Ganser, Arnold, Weber, Daniela, Sträng, Eric, Kestler, Hans A., Döhner, Hartmut, Bullinger, Lars, Döhner, Konstanze
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497712/ https://www.ncbi.nlm.nih.gov/pubmed/31048683 http://dx.doi.org/10.1038/s41467-019-09745-2

Ejemplares similares

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair
por: Herzig, Julia K., et al.
Publicado: (2017)

S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN
por: Rücker, Frank G, et al.
Publicado: (2023)

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
por: Teich, Katrin, et al.
Publicado: (2021)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
por: Schlenk, Richard F., et al.
Publicado: (2020)

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
por: Agrawal, Mridul, et al.
Publicado: (2019)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
por: Gaidzik, Verena I., et al.
Publicado: (2023)

Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype
por: Feurstein, Simone, et al.
Publicado: (2014)

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia
por: Zajac, Malgorzata, et al.
Publicado: (2017)

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
por: Nagel, Gabriele, et al.
Publicado: (2017)

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019)

Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
por: Schlenk, R. F., et al.
Publicado: (2023)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
por: Schlenk, R F, et al.
Publicado: (2017)

SEURAT: Visual analytics for the integrated analysis of microarray data
por: Gribov, Alexander, et al.
Publicado: (2010)

Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia
por: Zhai, Yanan, et al.
Publicado: (2022)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology
por: Klever, Marius-Konstantin, et al.
Publicado: (2023)

Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation
por: Braune, Jan, et al.
Publicado: (2022)

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers
por: Lueck, Sonja C., et al.
Publicado: (2016)

EU-Wide Access to High-quality, Affordable Precision Diagnostics: An EHA Position Paper
por: Macintyre, Elizabeth, et al.
Publicado: (2020)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
por: Heidel, Florian H., et al.
Publicado: (2013)

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
por: Thiel, V N, et al.
Publicado: (2017)

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
por: Feurstein, Simone, et al.
Publicado: (2018)

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
por: Jahn, Nikolaus, et al.
Publicado: (2022)

S120: MNX1-ACTIVATING ENHANCER HIJACKING EVENTS IN ACUTE MYELOID LEUKEMIA WITH DELETIONS ON CHROMOSOME 7Q
por: Riedel, Anna, et al.
Publicado: (2023)

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
por: Ng, Yuen Lam Dora, et al.
Publicado: (2022)

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
por: Owattanapanich, Weerapat, et al.
Publicado: (2021)

P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
por: Kelly, Katherine, et al.
Publicado: (2023)

The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements
por: Grasedieck, Sarah, et al.
Publicado: (2021)

Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study
por: Manz, Kirsi, et al.
Publicado: (2023)

Erratum to: Analysis, identification and visualization of subgroups in genomics
por: Völkel, Gunnar, et al.
Publicado: (2021)

Analysis, identification and visualization of subgroups in genomics
por: Völkel, Gunnar, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f7ojr7is3q9bjg5uknrk2rvo6n